Last edition
News about "Everest Medicine"
Everest Medicines Acquires Greater China Rights to Cardamyst Nasal Spray in USD 50 Million Deal
Everest Medicines has entered into an asset purchase agreement with Corxel Pharmaceuticals Hong Kong Limited to acquire exclusive rights to develop, manufacture, and commercialize Cardamyst (etripamil) nasal spray across Greater China, including mainland China, Hong Kong, Macao, and Taiwan.
Everest Medicine | 24/03/2026 | By Darshana | 143
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members